Some statistically significant differences between citalopram and other antidepressants for the acute phase treatment of major depression were found in terms of efficacy , tolerability and acceptability .
Citalopram was more efficacious than paroxetine and reboxetine and more acceptable than tricyclics , reboxetine and venlafaxine , however , it seemed to be less efficacious than escitalopram .
BACKGROUND Recent US and UK clinical practice guidelines recommend that second-generation antidepressants should be considered amongst the best first-line options when drug therapy is indicated for a depressive episode .
Systematic review s have already highlighted some differences in efficacy between second-generation antidepressants .
Citalopram , one of the first selective serotonin reuptake inhibitors ( SSRI ) introduced in the market , is one of these antidepressant drugs that clinicians use for routine depression care .
OBJECTIVES To assess the evidence for the efficacy , acceptability and tolerability of citalopram in comparison with tricyclics , heterocyclics , other SSRIs and other conventional and non-conventional antidepressants in the acute-phase treatment of major depression .
Changes in sleep polygraphic variables and clinical state in depressed patients during treatment with citalopram
Drug-induced improvement of depression may be mediated by changes in sleep physiology . The aim of this study was to relate changes in sleep polygraphic variables to clinical state during treatment with citalopram , a highly specific serotonin uptake inhibitor . Sixteen patients took part . The study was single-blind and uncontrolled . A 1-week wash-out period was followed by 1 week of placebo administration , a medication period of 5 weeks , and a 1-week placebo period . For the entire group a significant decrease of rapid eye movement sleep ( REMS ) and a significant lengthening of REMS latency were observed initially as well as at the end of treatment . No changes in sleep continuity were found , but non-REMS stage 2 ( percentage ) was significantly increased . On the basis of clinical change , as expressed by the scores of the Hamilton Rating Scale for Depression , at the end of the citalopram treatment the patient group was split in two halves : eight less and eight more improved patients . The groups did not differ with respect to any sleep polygraphic varible
Some statistically significant differences between citalopram and other antidepressants for the acute phase treatment of major depression were found in terms of efficacy , tolerability and acceptability .
Citalopram was more efficacious than paroxetine and reboxetine and more acceptable than tricyclics , reboxetine and venlafaxine , however , it seemed to be less efficacious than escitalopram .
BACKGROUND Recent US and UK clinical practice guidelines recommend that second-generation antidepressants should be considered amongst the best first-line options when drug therapy is indicated for a depressive episode .
Systematic review s have already highlighted some differences in efficacy between second-generation antidepressants .
Citalopram , one of the first selective serotonin reuptake inhibitors ( SSRI ) introduced in the market , is one of these antidepressant drugs that clinicians use for routine depression care .
OBJECTIVES To assess the evidence for the efficacy , acceptability and tolerability of citalopram in comparison with tricyclics , heterocyclics , other SSRIs and other conventional and non-conventional antidepressants in the acute-phase treatment of major depression .